AdaRx

ADARx Pharmaceuticals is a clinical-stage RNA therapeutics company based in San Diego developing next-generation genetic medicines that precisely silence the underlying causes of disease. The company leverages proprietary RNA targeting platforms and oligonucleotide delivery technologies — including inhibition, degradation, and mRNA editing — to address unmet needs across genetic, cardiovascular, cardiometabolic, complement-mediated, central nervous system, and metabolic diseases. Founded in 2019, ADARx is advancing a diverse clinical pipeline with a focus on delivering improved potency, precision, and durability for patients with chronic and life-threatening conditions.